Pulmatrix Net Worth
Pulmatrix Net Worth Breakdown | PULM |
Pulmatrix Net Worth Analysis
Pulmatrix's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Pulmatrix's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Pulmatrix's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Pulmatrix's net worth analysis. One common approach is to calculate Pulmatrix's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Pulmatrix's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Pulmatrix's net worth. This approach calculates the present value of Pulmatrix's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Pulmatrix's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Pulmatrix's net worth. This involves comparing Pulmatrix's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Pulmatrix's net worth relative to its peers.
Enterprise Value |
|
To determine if Pulmatrix is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Pulmatrix's net worth research are outlined below:
| Pulmatrix had very high historical volatility over the last 90 days | |
| Pulmatrix has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 7.3 M. Net Loss for the year was (14.12 M) with loss before overhead, payroll, taxes, and interest of (671 K). | |
| Pulmatrix currently holds about 42.91 M in cash with (15.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Pulmatrix has a frail financial position based on the latest SEC disclosures | |
| Latest headline from businesswire.com: PULM Stock Alert Halper Sadeh LLC Is Investigating Whether the Merger of Pulmatrix, Inc. Is Fair to Shareholders |
Pulmatrix uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Pulmatrix. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Pulmatrix's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Pulmatrix Target Price Consensus
Pulmatrix target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Pulmatrix's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Buy |
Most Pulmatrix analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Pulmatrix stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Pulmatrix, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationPulmatrix Target Price Projection
Pulmatrix's current and average target prices are 8.28 and 10.00, respectively. The current price of Pulmatrix is the price at which Pulmatrix is currently trading. On the other hand, Pulmatrix's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Pulmatrix Target Price
Know Pulmatrix's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pulmatrix is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pulmatrix backward and forwards among themselves. Pulmatrix's institutional investor refers to the entity that pools money to purchase Pulmatrix's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Hanson Mcclain Inc | 2024-12-31 | 3.0 | Northern Trust Investments N A | 2024-12-31 | 0.0 | Gradient Investments | 2024-09-30 | 0.0 | Advisor Group Holdings, Inc. | 2024-12-31 | 0.0 | Northwestern Mutual Wealth Management Co | 2024-12-31 | 0.0 | Renaissance Technologies Corp | 2024-12-31 | 109.1 K | Sbi Securities Co Ltd | 2024-12-31 | 66.2 K | Blackrock Inc | 2024-12-31 | 54.9 K | Geode Capital Management, Llc | 2024-12-31 | 36.9 K | Vanguard Group Inc | 2024-12-31 | 35.1 K | State Street Corp | 2024-12-31 | 13.9 K |
Follow Pulmatrix's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 28.6 M.Market Cap |
|
Project Pulmatrix's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.37) | (0.39) | |
| Return On Capital Employed | (0.44) | (0.46) | |
| Return On Assets | (0.37) | (0.39) | |
| Return On Equity | (0.71) | (0.74) |
When accessing Pulmatrix's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Pulmatrix's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Pulmatrix's profitability and make more informed investment decisions.
Evaluate Pulmatrix's management efficiency
Pulmatrix has return on total asset (ROA) of (0.1921) % which means that it has lost $0.1921 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.627) %, meaning that it created substantial loss on money invested by shareholders. Pulmatrix's management efficiency ratios could be used to measure how well Pulmatrix manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of February 2025, Return On Tangible Assets is likely to drop to -0.39. In addition to that, Return On Capital Employed is likely to drop to -0.46. At this time, Pulmatrix's Non Currrent Assets Other are very stable compared to the past year. As of the 25th of February 2025, Net Tangible Assets is likely to grow to about 37.6 M, while Non Current Assets Total are likely to drop about 8.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.67 | 5.38 | |
| Tangible Book Value Per Share | 5.67 | 5.38 | |
| Enterprise Value Over EBITDA | 0.25 | 0.26 | |
| Price Book Value Ratio | 0.34 | 0.36 | |
| Enterprise Value Multiple | 0.25 | 0.26 | |
| Price Fair Value | 0.34 | 0.36 | |
| Enterprise Value | -4.2 M | -4.4 M |
The decision-making processes within Pulmatrix are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue 2.1425 | Revenue | Quarterly Revenue Growth (0.79) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pulmatrix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pulmatrix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pulmatrix insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Siegert Michelle over three months ago Disposition of 25000 shares by Siegert Michelle of Pulmatrix at 1.06 subject to Rule 16b-3 | ||
Cabell Christopher over three months ago Acquisition by Cabell Christopher of 22100 shares of Pulmatrix at 0.3701 subject to Rule 16b-3 | ||
Gillis Steven over six months ago Acquisition by Gillis Steven of 111 shares of Pulmatrix at 110.0 subject to Rule 16b-3 | ||
Gillis Steven over six months ago Disposition of 880 shares by Gillis Steven of Pulmatrix at 28.0 subject to Rule 16b-3 | ||
Teofilo Raad over a year ago Acquisition by Teofilo Raad of 34900 shares of Pulmatrix subject to Rule 16b-3 |
Pulmatrix Corporate Filings
8K | 14th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 22nd of January 2025 Other Reports | ViewVerify | |
| 17th of May 2024 Other Reports | ViewVerify |
Pulmatrix Earnings Estimation Breakdown
The calculation of Pulmatrix's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Pulmatrix is estimated to be 0.0 with the future projection ranging from a low of 0.0 to a high of 0.0. Please be aware that this consensus of annual earnings estimates for Pulmatrix is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.00 Lowest | Expected EPS | 0.00 Highest |
Pulmatrix Earnings Projection Consensus
Suppose the current estimates of Pulmatrix's value are higher than the current market price of the Pulmatrix stock. In this case, investors may conclude that Pulmatrix is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Pulmatrix's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 1 | 67.75% | -0.57 | 0.0 | -2.64 |
Pulmatrix Earnings per Share Projection vs Actual
Actual Earning per Share of Pulmatrix refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Pulmatrix predict the company's earnings will be in the future. The higher the earnings per share of Pulmatrix, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Pulmatrix Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Pulmatrix, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Pulmatrix should always be considered in relation to other companies to make a more educated investment decision.Pulmatrix Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Pulmatrix's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-03-28 | 2023-12-31 | -1.04 | -0.57 | 0.47 | 45 | ||
2023-11-09 | 2023-09-30 | -1.05 | -1.03 | 0.02 | 1 | ||
2023-08-10 | 2023-06-30 | -1.23 | -1.04 | 0.19 | 15 | ||
2023-03-30 | 2022-12-31 | -1.44 | -1.14 | 0.3 | 20 | ||
2022-11-10 | 2022-09-30 | -1.51 | -1.45 | 0.06 | 3 | ||
2022-08-08 | 2022-06-30 | -1.51 | -1.36 | 0.15 | 9 | ||
2022-05-12 | 2022-03-31 | -1.41 | -1.51 | -0.1 | 7 | ||
2022-03-29 | 2021-12-31 | -1.6 | -2.43 | -0.83 | 51 | ||
2021-11-10 | 2021-09-30 | -1.4 | -3.0 | -1.6 | 114 | ||
2021-08-10 | 2021-06-30 | -2 | -1.4 | 0.6 | 30 | ||
2021-05-11 | 2021-03-31 | -2 | -1.8 | 0.2 | 10 | ||
2021-03-23 | 2020-12-31 | -3.8 | -1.0 | 2.8 | 73 | ||
2020-11-12 | 2020-09-30 | -4.4 | -0.8 | 3.6 | 81 | ||
2020-08-07 | 2020-06-30 | -7.6 | -1.0 | 6.6 | 86 | ||
2020-05-14 | 2020-03-31 | -4.4 | -4.6 | -0.2 | 4 | ||
2020-03-26 | 2019-12-31 | -5.4 | -3.2 | 2.2 | 40 | ||
2019-11-01 | 2019-09-30 | -6.8 | -3.6 | 3.2 | 47 | ||
2019-08-05 | 2019-06-30 | -7.8 | -8.2 | -0.4 | 5 | ||
2019-05-15 | 2019-03-31 | -11.8 | -12.6 | -0.8 | 6 | ||
2019-02-19 | 2018-12-31 | -38 | -5.6 | 32.4 | 85 | ||
2018-11-14 | 2018-09-30 | -1.8 | -1.0 | 0.8 | 44 | ||
2018-08-03 | 2018-06-30 | -1.7 | -1.3 | 0.4 | 23 | ||
2018-05-11 | 2018-03-31 | -0.19 | -0.24 | -0.05 | 26 | ||
2018-03-13 | 2017-12-31 | -0.25 | -2.1 | -1.85 | 740 | ||
2017-11-09 | 2017-09-30 | -3 | -0.22 | 2.78 | 92 | ||
2017-08-04 | 2017-06-30 | -3 | -0.29 | 2.71 | 90 | ||
null | null | null | null | null | 0 |
Pulmatrix Corporate Management
| MBA CMA | Interim Officer | Profile | |
| Alexander Klibanov | Founder | Profile | |
| Margaret MD | Chief Officer | Profile | |
| David JD | Advisor | Profile | |
| Aidan Curran | VP Affairs | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Revenue Per Share | Quarterly Revenue Growth (0.79) | Return On Assets | Return On Equity |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.